Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Algeta Articles

Fast FDA approval for Bayer's new drug for advanced prostate cancer, Xofigo

16 May 2013

FDA priority review for Algeta and Bayer's prostate cancer agent radium-223

14 February 2013

US NRC rules sites can procure radium-223 dichloride for Algeta/Bayer's prostate cancer candidate

14 January 2013

FDA accepts NDA filings from Pfizer/Ligand and Actelion; Bayer submits Alpharadin

16 December 2012

Bayer files prostate cancer drug Alpharadin in the EU

13 December 2012

Algeta and Ablynx collaborate on tumor-targeting Nanobodies

22 November 2012

Algeta prepares for Alpharadin US launch, opening US base

19 September 2012

Algeta takes up option to co-promote Alpharadin in the USA

13 April 2012

Four new drugs will change prostate cancer care, says US expert

19 February 2012

Bayer and Algeta’s Alpharadin efficacy confirmed; Almirall to market Xarelto in Spain

13 February 2012

News briefs from breast cancer meeting

12 December 2011

Expanding Norwegian cancer cluster adds new start-ups

31 October 2011

Positive first Phase III trial of an alpha-pharmaceutical, Bayer’s Alpharadin

26 September 2011

US FDA fast-tracks Bayer and Algeta’s prostate drug Alpharadin

23 August 2011

Bayer's Alpharadin improves survival in prostate cancer; VEGF Trap-Eye filed in EU

7 June 2011

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS